LONDON BROKER RATINGS: United Utilities raised; HSBC cuts easyJet
20th Nov 2024 09:53
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - The FTSE 100 is called to open flat on Wednesday, after a hotter than expected UK inflation reading. Read More
(Alliance News) - Women with incurable breast cancer in England and Wales will not be offered a life-extending drug on the national health service after talks between the NHS spending watchdog and its manufacturer ended without an agreement on price for the third time. Read More
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Friday last week and not separately reported by Alliance News: Read More
(Alliance News) - AstraZeneca PLC on Monday said that the EU's Committee for Medicinal Products for Human Use, or CHMP, recommended its cancer drug Tagrisso as treatment for a form of lung cancer. Read More
(Alliance News) - Stock prices in London closed lower, while equities in New York opened in the red after Federal Reserve Chair Jerome Powell dashed rate cut hopes overnight. Read More
(Alliance News) - Stock prices in London were mostly higher at midday on Friday, despite disappointing data including weaker-than-expected gross domestic product growth. Read More
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Thursday and Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
Merck & Co Inc and AstraZeneca PLC - Pharmaceutical companies based in Rahway, New Jersey and Cambridge, England, respectively - Phase 3 Komet trial shows statistically significant and clinically meaningful improvement in objective response rate in adult neurofibromatosis patients treated with AstraZeneca and Merck's joint-developed medication Koselugo. The condition is a rare progressive genetic disease in which tumours develop on nerve sheaths and may lead to disfigurement, motor dysfunction, pain, airway dysfunction, visual impairment and bladder or bowel dysfunction. Koselugo is approved to treat children with the disease but there is little intervention available for adults. Read More
(Alliance News) - London's FTSE 100 resumed its downward path on Tuesday, as a mixed bag of earnings, political uncertainty, and stronger-than-expected wage growth dented the mood. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said it took the detention of its China president "very seriously" as it raised 2024 guidance after a strong third quarter. Read More
(Alliance News) - Stocks opened in the red in London on Tuesday morning, as Shell won in a Dutch court. Read More
(Alliance News) - Angle PLC on Monday said its in-vitro diagnostic Parsortix system was successfully used in a non-small cell lung cancer study to help identify patients becoming resistant to treatment. Read More
(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps. Read More
(Alliance News) - AstraZeneca PLC said Thursday that the head of its China operations had been detained, after reports the firm was under investigation for potentially illegal data collection and drug imports. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - AstraZeneca PLC on Tuesday took the rare step of addressing a sharp fall in the company's share price. Read More
(Alliance News) - London's FTSE 100 closed just the wrong side of the line on Tuesday, bucking a more upbeat global mood, weighed by sharp falls in AstraZeneca and Schroders. Read More